Literature DB >> 7559501

Two adjacent N-terminal glutamines of BM-40 (osteonectin, SPARC) act as amine acceptor sites in transglutaminaseC-catalyzed modification.

C Hohenadl1, K Mann, U Mayer, R Timpl, M Paulsson, D Aeschlimann.   

Abstract

The extracellular matrix protein BM-40 (osteonectin, SPARC) has recently been shown to be a major target for transglutaminase-catalyzed cross-linking in differentiating cartilage. In the present study we demonstrate that recombinant human BM-40 can be modified with [3H]putrescine in a 1:1 molar ratio by transglutaminaseC (tissue transglutaminase). Residues Gln3 and Gln4 were identified as major amine acceptor sites. This was confirmed with several mutant proteins, including deletions in the N-terminal domain I of BM-40, site-directed mutagenesis of the reactive glutamines, and fusion of the seven-amino acid-long N-terminal sequence (APQQEAL) to an unrelated protein. The results showed that the N-terminal target site is sufficient for modification by transglutaminase but at a low level. For high efficiency amine incorporation an intact domain I is required. The conservation of at least one of the transglutaminase target glutamines in the known vertebrate BM-40 sequences and their absence in an invertebrate homologue point to an important, but yet unknown, role of this modification in vertebrates.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559501     DOI: 10.1074/jbc.270.40.23415

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Reactivity of the N-terminal region of fibronectin protein to transglutaminase 2 and factor XIIIA.

Authors:  Brian R Hoffmann; Douglas S Annis; Deane F Mosher
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

Review 2.  Cultured epithelial autografts: diving from surgery into matrix biology.

Authors:  M Raghunath; M Meuli
Journal:  Pediatr Surg Int       Date:  1997-09       Impact factor: 1.827

3.  Cross-linking of the dermo-epidermal junction of skin regenerating from keratinocyte autografts. Anchoring fibrils are a target for tissue transglutaminase.

Authors:  M Raghunath; B Höpfner; D Aeschlimann; U Lüthi; M Meuli; S Altermatt; R Gobet; L Bruckner-Tuderman; B Steinmann
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

4.  Method for screening and MALDI-TOF MS sequencing of encoded combinatorial libraries.

Authors:  Bi-Huang Hu; Marsha Ritter Jones; Phillip B Messersmith
Journal:  Anal Chem       Date:  2007-08-23       Impact factor: 6.986

5.  Cellular Factor XIIIA Transglutaminase Localizes in Caveolae and Regulates Caveolin-1 Phosphorylation, Homo-oligomerization and c-Src Signaling in Osteoblasts.

Authors:  Shuai Wang; Mari T Kaartinen
Journal:  J Histochem Cytochem       Date:  2015-07-31       Impact factor: 2.479

6.  Facile coupling of synthetic peptides and peptide-polymer conjugates to cartilage via transglutaminase enzyme.

Authors:  Marsha Elizabeth Ritter Jones; Phillip B Messersmith
Journal:  Biomaterials       Date:  2007-09-17       Impact factor: 12.479

7.  Transglutaminase 6: a protein associated with central nervous system development and motor function.

Authors:  Helen Thomas; Konrad Beck; Magdalena Adamczyk; Pascale Aeschlimann; Martin Langley; Radu C Oita; Lars Thiebach; Martin Hils; Daniel Aeschlimann
Journal:  Amino Acids       Date:  2011-10-08       Impact factor: 3.520

8.  Plasmodium falciparum liver stage antigen-1 is cross-linked by tissue transglutaminase.

Authors:  William S Nicoll; John B Sacci; Carlo Rodolfo; Giuseppina Di Giacomo; Mauro Piacentini; Zoe Jm Holland; Christian Doerig; Michael R Hollingdale; David E Lanar
Journal:  Malar J       Date:  2011-01-21       Impact factor: 2.979

9.  A holistic approach to dissecting SPARC family protein complexity reveals FSTL-1 as an inhibitor of pancreatic cancer cell growth.

Authors:  Katrina Viloria; Amanda Munasinghe; Sharan Asher; Roberto Bogyere; Lucy Jones; Natasha J Hill
Journal:  Sci Rep       Date:  2016-11-25       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.